Cardiol Therapeutics Inc (CRDL:CA) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart diseases.
The company’s lead product, CardiolRx, is an oral cannabidiol formulation under clinical development for various heart conditions.
Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor’s premium features. Claim your discount here!
Expected Quarterly Earnings Report of Cardiol Therapeutics Inc:
Cardiol Therapeutics is anticipated to release its financial results for the fourth quarter of 2024 on March 27, 2025. Analyst estimates suggest an expected loss per share of CAD 0.127 for this quarter.
Looking ahead, the company is projected to report a loss per share of CAD 0.130 for the first quarter of 2025, with the earnings release scheduled for May 20, 2025.
Stock Target Advisor’s Analysis on Cardiol Therapeutics Inc:
Analyst consensus indicates a “Moderate Buy” rating for Cardiol Therapeutics, based on evaluations from two analysts. The average one-year price target is CAD 6.88, with forecasts ranging from a low of CAD 5.94 to a high of CAD 8.00. These projections suggest a significant potential upside from the current trading price.
Conclusion:
Cardiol Therapeutics Inc. continues to advance its clinical programs targeting heart diseases, with upcoming earnings reports expected to provide further insights into the company’s financial health and operational progress.
Analyst projections and ratings reflect optimism about the company’s future performance, indicating potential growth opportunities for investors.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
